Thermo Fisher inaugurates its new clinical research laboratory in Wisconsin

Thermo Fisher Scientific (MA, USA) has now finished and installed its new 72,500-square-foot clinical research laboratory at its Good Manufacturing Practices (GMP) facility in Middleton, Wisconsin.

The US scientific services supplier invested USD $58 million in the new facility, aiming to improve the site’s chemistry, manufacturing and control (CMC) analytical capabilities as part of its clinical development and laboratory services. This expansion is anticipated to increase the site’s 2,300-employee workforce by 350 scientists and laboratory support workers.

“As research in biopharmaceutical therapies continues to rapidly expand, we are excited to expand our overall capacity and capabilities in laboratory services to help our customers deliver therapies that meet the highest quality and safety standards for patients,” explains Leon Wyszkowski, President of analytical services and clinical research at Thermo Fisher.

Thermo Fisher maintains that the GMP site delivers analytical services for small molecules and biologics. These services comprise biopharmaceuticals, inhaled pharmaceuticals and device testing, cell and gene therapy, protein characterization and mass spectrometry analysis for all phases across the drug development process.

You may also be interested in:

• Fujifilm plans to spend $4.5 billion by 2028 towards instituting new biopharmaceutical plants
• Manchester researchers help secure £49.35m to boost mass spectrometry research
• Roche Opens €90m Center Dedicated to the Development of Gene Therapies

Prior to this year, Thermo Fisher announced the inclusion of biosafety testing to its GMP services at the Middleton facility. With this new capability, coupled with the addition of the new building, the site now provides a comprehensive range of end-to-end laboratory services.